S
Stephan A. Grupp
Researcher at Children's Hospital of Philadelphia
Publications - 396
Citations - 44427
Stephan A. Grupp is an academic researcher from Children's Hospital of Philadelphia. The author has contributed to research in topics: Chimeric antigen receptor & Transplantation. The author has an hindex of 77, co-authored 366 publications receiving 34450 citations. Previous affiliations of Stephan A. Grupp include University of Pennsylvania & St. Jude Children's Research Hospital.
Papers
More filters
Journal ArticleDOI
Biomarker Profiling Differentiates Sepsis from Cytokine Release Syndrome in Chimeric Antigen Receptor T-Cell Therapy for Acute Lymphoblastic Leukemia (ALL)
Simon F. Lacey,Pamela A. Shaw,David T. Teachey,Scott L. Weiss,Fang Chen,Vanessa E. Gonzalez,Noelle V. Frey,David L. Porter,Shannon L. Maude,Stephan A. Grupp,Edward Pequignot,Carl H. June,J. Joseph Melenhorst +12 more
TL;DR: These current studies compare biomarker profiles in CRS and sepsis, and attempt to identify a profile that would discriminate between the two clinical syndromes, particularly at the time of ICU admission.
Journal ArticleDOI
Comprehensive Serum Proteome Profiling of Cytokine Release Syndrome and Immune Effector Cell Associated Neurotoxicity Syndrome in B-Cell ALL Patients Receiving CART19.
Caroline Diorio,Rawan Shraim,Regina M. Myers,Edward M. Behrens,Scott W. Canna,Hamid Bassiri,Richard Aplenc,Chakkapong Burudpakdee,Fang Chen,Amanda M. DiNofia,Saar Gill,Vanessa E. Gonzalez,Michele P. Lambert,Allison Barz Leahy,Bruce L. Levine,Robert B. Lindell,Shannon L. Maude,J. Joseph Melenhorst,Haley Newman,Jessica Perazzelli,Alix E. Seif,Simon F. Lacey,Carl H. June,David M. Barrett,Stephan A. Grupp,David T. Teachey +25 more
TL;DR: The fundamental role of the interferon gamma pathway in driving CRS is demonstrated which suggests that CRS and carHLH are overlapping rather than distinct phenomena which has important treatment implications.
Journal ArticleDOI
Association of higher lung dose received during total body irradiation for allogeneic hematopoetic stem cell transplantation in children with acute lymphoblastic leukemia with inferior progression-free and overall survival: A report from the Children’s Oncology Group.
Natia Esiashvili,Xiaomin Lu,Stephen P. Hunger,Thomas E. Merchant,Patrick A. Brown,Donna A. Wall,Stephan A. Grupp,Michael A. Pulsipher +7 more
TL;DR: The relationship between lung radiation dose and transplant-related mortality (TRM), relapse-free (RFS) and overall survival (OS) in children and adolescents undergoing TBI-based HSCT for acute lymphoblastic leukemia (ALL) on Children’s Oncology Group trial ASCT0431 is examined.
Journal ArticleDOI
Management of Coagulopathy Associated with CTL019 CAR T-Cell Therapy
Jochen Büchner,Stephan A. Grupp,Stephan A. Grupp,Shannon L. Maude,Shannon L. Maude,Hidefumi Hiramatsu,David T. Teachey,Patricia A. Wood,Rakesh Awasthi,Lan Yi,Barbara De Moerloose +10 more
TL;DR: In this paper, the authors outline the treatment guidelines established and US and global multicenter experience with CTL019-associated coagulopathy in 97 pts treated with CAR-019.
Proceedings ArticleDOI
Abstract PR06: T cells engineered with a chimeric antigen receptor (CAR) targeting CD19 (CTL019) produce complete responses and long-term persistence without GVHD in children with relapsed, refractory ALL
Stephan A. Grupp,Shannon L. Maude,Richard Aplenc,David M. Barrett,Michael Kalos,Bruce L. Levine,Manuel Lichtman,Susan R. Rheingold,Angela Shen,Christine Strait,David T. Teachey,Patricia A. Wood,Carl H. June +12 more
TL;DR: CTL019 cells are T cells genetically engineered to express an anti-CD19 scFv coupled to CD3ζ signaling and 4-1BB costimulatory domains that can undergo robust in-vivo expansion and can persist for 15 mo or longer in pts with relapsed ALL, and has promise as a salvage therapy for patients who relapse after allo-SCT.